Emerging research indicates that individuals with asthma have an increased risk of cognitive impairment, yet the associations of asthma with neural correlates of memory remain relatively unknown. The hippocampus is the predominant neural structure involved in memory, and alterations in the hippocampal metabolic profile are observed in individuals with mild cognitive impairment. We therefore hypothesized that individuals with asthma may have altered hippocampal metabolites compared to healthy controls.
Introduction
Emerging research indicates that individuals with asthma across the life span suffer from higher rates of cognitive and memory impairment compared to the healthy population (1); however, biological correlates of these behavioural deficits remain unknown. A recent metaanalysis synthesizing over 4148 participants, found a medium effect sized relation between asthma and reduced cognitive function (1) , and in a large community sample of individuals over 55 years, individuals with asthma had a 78% increased risk for the presence of mild cognitive impairment (2) . Despite an accumulation of studies indicating the risk of cognitive deficits in asthma, the impact of asthma on neural regions involved in memory and their chemistry remains relatively unexplored. Central nervous system (CNS) processes in asthma and dyspnea have recently attracted attention (3; 4; 5; 6; 7; 8); however, any influence of asthma on neural regions involved in memory, has only been explored in one study, observing smaller hippocampal volumes in middle aged individuals with asthma (9). The influence of asthma on neural chemistry has, to the best of our knowledge, not been explored.
The primary neural region involved in memory is the hippocampus, a structure integral for encoding episodic memory and memory consolidation (10). Changes in hippocampal volume and chemistry often coincide with reduced cognitive performance (11, 12); however, no studies have examined the hippocampal chemistry of patients with asthma.
Neuroimaging technology has advanced from purely structural insights and functional imaging to non-invasive identification of chemical metabolite markers of CNS activity through A C C E P T E D M A N U S C R I P T 5 myo-inositol (MI), a putative marker of glial activation; glutamate (Glu), an excitatory neurotransmitter; and creatine (Cr), which additionally includes phosphocreatine and is used as a marker for cellular energy and metabolism (14) . NAA is the second most concentrated molecule in the brain after Glu and provides a critical source of acetate for myelin lipid synthesis in oligodendrocytes. NAA facilitates energy metabolism in neuronal mitochondria, and is therefore used as a putative marker of neuronal number, health, and viability (13) . MI is preferentially concentrated in glial cells and is used as a putative marker of microglial activation. Neuroinflammation is characterized by an increase in MI, and an increase of MI in neural regions has been found to be associated with and precede dementia (15; 16) . Glu is the most prevalent excitatory neurotransmitter and its role is critical for the establishment of long term potentiation (LTP), which strengthens neural connections leading to gains in working and declarative memory (17) . Cr is a precursor of adenosine triphosphate and therefore an indicator of cellular energy metabolism and storage, thought to be a relatively stable neural metabolite in both health and disease (13, 14) . Abnormalities in these four neural metabolites (deficits, elevations, or changes in their ratios) are observed in those with cognitive impairment, and have even been found to predict disease progression and future cognitive decline (18; 19; 15; 16; 17) .
Hippocampal gray matter volume deficits and alterations in hippocampal metabolites are additionally observed in chronic pulmonary inflammatory disease states, including COPD (20; 21; 22) ; however, to the best of our knowledge, there are no studies examining hippocampal metabolites in asthma. Patients with asthma may be uniquely influenced by natural sequelae of a chronic systemic inflammatory disease, moments of hypoxia, asthma medication, and/or behavioural influences commonly associated with asthma including diminished sleep quality.
Outside of the context of asthma, these factors independently demonstrate detectable influences
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A C C E P T E D M A N U S C R I P T 6 on the hippocampus and cognition in both human and animal studies (23; 24; 25; 26) . We therefore hypothesized that hippocampal metabolites would be altered in asthma compared to healthy controls, and further hypothesized that lower levels of NAA and Glu would be associated with poorer cognitive function. We additionally hypothesized that asthma medication would demonstrate influences on hippocampal metabolites. As prior research suggests that hippocampal volume can be reduced in asthma (9), we also analysed hippocampal structure to exclude the possibility that differences in metabolite levels were secondary to hippocampal volume. Studies in patients receiving chronic corticosteroid treatment have found no significant differences between left and right hippocampal metabolites (11), consistent with reviews of hippocampal metabolites in mild cognitive impairment (13) . Individuals with greater cognitive deterioration have shown lower levels of NAA in the left temporal lobe (13), and we therefore focused our analyses on the left hippocampus.
Methods and Materials
Additional methodological details are provided in the online supplement.
Participants
Twenty patients with a physician's diagnosis of asthma were compared to twenty ageand gender-matched healthy controls. Exclusion criteria for all participants included: neurological or cardiovascular disease, any other chronic inflammatory disease, lung disease besides asthma, history of smoking, current major depressive episode, current or recent history (within one year) of substance related disorders including alcohol abuse, recreational drug use, history of any manic episode, and symptoms of schizophrenia, bipolar disorder, or psychosis.
Individuals who used corticosteroids (oral and injected) within the past 3 months were additionally excluded. As a precaution for the scanning environment, participants with values of
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Magnetic Resonance Imaging Acquisition and Analysis
Structural MRI was conducted on the 3T scanner described above, immediately prior to 
Statistical Analyses
Independent two sample t-tests calculated between group (asthma vs. healthy) differences in hippocampal metabolites and volume. Non-parametric Mann-Whitney test was calculated for group differences in Glu, as it violated assumptions of normality. Pearson partial correlations calculated relations among: hippocampal metabolites, cognitive scores, medication use and asthma control, controlling for hippocampal volume. IBM SPSS (Version 24) was used for analyses, and all variables demonstrated properties of normality. As group differences were observed in Cr, total metabolite values in reference to water, rather than in reference to Cr, were used for analyses according to recommendations of Tumati and colleagues (18) . MRS data was
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Questionnaire and behavioral measures were retained for the entire sample.
Results

Participants
Participants were on average 25 years old and had a high education level (most were recruited from a local university). There was neither a statistically significant difference between the groups on demographics, years of education, nor physical characteristics (Table 1) .
Of those with asthma, 13 had well-controlled asthma with ACT values >19, and only two participants reported a single lifetime occurrence of an asthma-related emergency room visit, none within the past year (Table 1) . Asthma severity ranged from intermittent to severe, based on National Asthma Education and Prevention Program guidelines (33) ( Table 1 ). Individual classifications of asthma severity, asthma control scores, and medication prescriptions are provided in the supplement.
Differences between Asthma and Healthy Groups
Individuals with asthma had lower levels of both NAA, t (33) 
Hippocampal Metabolites and Cognitive Function
A C C E P T E D M A N U S C R I P T for all participants, suggesting that those with higher levels of these metabolites, in particular Glu, performed better on a measure of global cognitive function (Table 3 , Figure 3 ). In individuals with asthma only, the correlations controlling for hippocampal volume followed a similar pattern; however, they were not statistically significant (Online Supplement).
Hippocampal Metabolites and Asthma Medication
Frequency of short-acting bronchodilator use in the past week was negatively correlated clinically recommended for long-term asthma control, had higher levels of Cr (Table 4) .
Hippocampal Metabolites, Asthma Control, and Cognitive Function
Hippocampal metabolites were not significantly correlated with asthma control; however, asthma control for the week before the imaging assessment, measured by the ACQ, was correlated with the MoCA, (r=-.46, p=.040), indicating that those with poorer asthma control had lower cognitive scores (Table 3, Figure 5 ). This finding was no longer significant when controlling for age.
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Additional results of metabolite/Cr ratios and exploratory correlations among metabolites, disease duration and asthma-related nocturnal awakenings are included in the Online Supplement.
Discussion
Key findings
The present work demonstrates that in younger individuals with asthma, there are substantial changes in the hippocampal chemical profile. Even in the absence of cognitive impairment, those with asthma had reductions in both hippocampal NAA, a marker of neuronal integrity and
Cr, a marker of cellular energy metabolism. These metabolites, in particular Glu, were additionally related to lower cognitive performance, after controlling for hippocampal volume.
There was no group difference in hippocampal volume in this cognitively healthy sample, which was on average 25 years younger than that of previous studies observing hippocampal volume deficits in asthma (9). However, the changes already observed in hippocampal metabolites in asthma before the onset of gross structural changes, may inform our understanding of the biological contributions to cognitive impairment observed in individuals with asthma over the lifespan.
Hippocampal metabolites in asthma
Our findings of reduced hippocampal NAA, already present in younger patients with asthma compared to age and gender matched healthy controls, complement previous observations of hippocampal volume deficits (9) and increased risks of mild cognitive impairment (2) in middle-aged individuals with asthma and affirm the influence of this chronic inflammatory disease not only on hippocampal structure, but also on its chemical composition. NAA is
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Despite the absence of cognitive deficits in this younger sample, there are already differences in hippocampal NAA in individuals with asthma, which may precede future cognitive decline.
While the exact comparison of total NAA values observed in the present study to those previously reported is limited due to fewer studies reporting total NAA, differences in scanner In addition to NAA, reductions in hippocampal Cr were observed in individuals with asthma. Cr is a marker of cellular energy thought to be stable neural metabolite in health and disease (13, 14) . As such, it has been used routinely as a reference for other metabolites.
However, individuals with cognitive impairment have demonstrated reductions in hippocampal
Cr, raising concerns for a potential Cr confound if metabolite/Cr ratios only are reported (for review see 18). As MRS technology has developed, a water reference can now be captured in the same scan, minimizing a potential confound of Cr, if it is influenced by disease process. The
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Despite similar levels of cognitive functioning across groups, the present findings may indicate pre-clinical influences of asthma control on global cognitive function. Poorer asthma control was correlated with lower cognitive scores, consistent with previous studies identifying variability in diurnal peak flow (used as a proxy for airway hyperreactivity, which is a hallmark of asthma) as the strongest predictor of cognitive function (36). While it cannot be ruled out that poorer cognitive function leads to poorer asthma control with this cross-sectional study design, these first findings extend hypothesized influences of asthma on cognition beyond asthma severity (1).
While future longitudinal research is needed to identify specific mechanisms for cognitive impairment in asthma, the present findings of deficits in markers of hippocampal neuronal viability, cellular energy metabolism and their relations with poorer global cognitive scores provides first insight into neural processes that may contribute to poorer cognitive function observed in individuals with asthma (1).
Potential mechanisms
There are a number of potential explanations for the changes observed in these hippocampal metabolites. Although this study was not designed to elucidate the specific mechanisms of medication, exploratory analyses found evidence for positive effects of inhaled corticosteroids on Cr, NAA, and Glu. In contrast to high systemic doses of corticosteroids, local administration of this medication in small doses leads to better control of asthma (41) and therefore may have helped avoid some of the adverse CNS asthma sequelae. The additionally observed associations between more frequent rescue inhaler usage and lower levels of Cr, NAA, and Glu would be consistent with that interpretation. When individuals with asthma followed clinically recommended medication guidelines to achieve proper control (e.g. use of maintenance medication rather than relying on more frequent use of rescue inhalers; 33), their hippocampal metabolites were more in line with those observed in the healthy sample. However, medication manipulation studies are needed to draw any further claims beyond this cross sectional association.
Third, hypoxia could be speculated to play a role, given its demonstrated influence on hippocampal structure, function and cognitive behavior in both animal and human studies (42) .
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While mechanistically probable, prolonged moments of hypoxia are less frequent in physician monitored cases of controlled asthma and lifetime visits to the emergency room due to asthma exacerbation in this sample were infrequent (Table 1) .
It is additionally possible that reductions in NAA and Cr may be influenced indirectly by behavioral factors common in chronic disease states, rather than the direct influence of asthma or its treatment. Sleep disruption, which is common in asthma, can influence hippocampal chemistry independently (43) 
Further considerations
This is the first study, to the best of our knowledge, to test differences in the hippocampal metabolic profile of individuals with and without asthma, and further explore the relations between disease variables, cognition, and neural chemistry. This study not only provides first evidence of absolute differences in hippocampal neuronal integrity, but additionally highlights their importance, along with asthma control, in cognitive function. Note, independent samples (two-tailed) t test found no statistically significant difference between groups on any variables. Ranges of questionnaire scores are provided in parentheses after each measure. ACT is scored with higher values indicating better control and ACQ is scored with lower values indicating better control. a Asthma severity was calculated for participants on short-term medication and for those on maintenance medication whose asthma was well controlled according to NIH/NAEPP (2007) severity and medication step therapy guidelines. Two individuals who were on maintenance medication and did not have wellcontrolled asthma according to the ACT, were therefore excluded from severity classification.
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